Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04350125 · ClinicalTrials.gov registry record · Phase 1
PRP for the Treatment of Erectile Dysfunction (ED)
A Phase 1 study of Erectile Dysfunction, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT04350125: Completed Phase 1 study of Erectile Dysfunction, sponsored by Mayo Clinic.
NCT04350125 is a Phase 1 study of Erectile Dysfunction that has completed, run by Mayo Clinic. The registered enrollment target is 4 participants, below the 232-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04350125, a Phase 1 study of Erectile Dysfunction, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers are trying to determine the safety and efficacy of Platelet Rich Plasma (PRP) in the treatment of Erectile Dysfunction (ED).
Primary Outcome
Number of participants to experience treatment-related adverse events defined as reaction in the skin (e.g., swelling, erythema, and warmth), injection site discomfort, penile pain, change in penile appearance, novel sexual concerns and any systemic reactions seen by the investigators, or concerns expressed by patients.
Conditions Studied
Interventions
- BIOLOGICAL Autologous Platelet Rich Plasma
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2023-10-23 |
| Phase | Phase 1 |
What the finished NCT04350125 record still lists
NCT04350125 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 232-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Erectile Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which Autologous Platelet Rich Plasma is the first listed.
NCT04350125 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04350125 about?
NCT04350125 is a clinical study titled "PRP for the Treatment of Erectile Dysfunction (ED)". Researchers are trying to determine the safety and efficacy of Platelet Rich Plasma (PRP) in the treatment of Erectile Dysfunction (ED).
What is the current status of trial NCT04350125?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2022-03-04. Estimated completion is 2023-10-23.
What conditions does trial NCT04350125 study?
This clinical trial studies the following conditions: Erectile Dysfunction.
What interventions are being tested in trial NCT04350125?
The interventions under investigation include: Autologous Platelet Rich Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04350125?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04350125 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erectile Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04350125's enrollment target sits among peer trials
4 34th of 33 the lowest of 33 other Erectile Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Erectile Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects
RECRUITING · Phase 1
-
Drug Interaction Study of Avanafil and Enalapril or Amlodipine
COMPLETED · Phase 1
-
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
RECRUITING · NA
-
Double-S: a Wearable Device for Erectile Dysfunction
RECRUITING · NA
-
Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED
RECRUITING · NA
-
The Impact of Dietary Pattern on Erectile Function
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI